Partial
Mostly Aligned
Patient Risk:
Low
Summary
Partial alignment. The claims reflect several label-supported considerations around atorvastatin interactions with niacin-containing therapies and general monitoring. However, a substantial number of the extracted claims are not explicitly stated in the label, and several patient-facing cautions are not directly present in the exact label language.
Category Scores
Accurate Statements
If the 'vitamin B' product also includes additional ingredients (for example, niacin in 'B-complex' products, or other lipid-lowering agents), then the interaction risk can change.
5.1, 7
Niacin (vitamin B3) is more likely than other B vitamins to change lipid treatment risk profiles when combined with a statin.
5.1
Statin + niacin combinations have been associated with higher monitoring needs for muscle-related problems and liver enzyme elevations compared with a statin alone.
5.1, 5.2
Clinicians often weigh the benefit versus risk and monitor labs when combining atorvastatin with niacin.
5.1
Atorvastatin can raise liver enzymes in some people.
5.2
Atorvastatin can rarely cause muscle injury.
5.1
If you notice unusual muscle pain, weakness, or dark urine, contact a clinician promptly and ask whether to pause the statin while labs are checked.
5.1
Niacin (B3) in any dose should be watched as an ingredient in B-complex or high-dose vitamin B products.
5.1
Talk to a pharmacist or prescriber before combining atorvastatin with vitamin B supplements if you’re taking other medications that affect statin levels (for example, strong CYP3A4 inhibitors).
7
Unsupported Statements
For most people, standard over-the-counter vitamin B supplements (like B12, folate, and typical doses of B6) do not have a well-known, clinically significant interaction with atorvastatin.
Not explicitly stated in the label; label discusses interactions with niacin and other agents but does not characterize a general lack of interaction for standard B vitamins.
Very high-dose B6 over long periods can cause nerve problems on its own, which can confuse symptom reporting (tingling/numbness) when people are also watching for statin side effects.
Not specifically described in the label; no mention of B6 neuropathy or symptom conflation in the labeling provided.
If your supplement is actually niacin-containing, it’s worth checking the exact ingredient list.
Not explicitly stated as an instruction in the label; general labeling emphasizes consulting healthcare professionals but not a specific prompt to check ingredient lists for niacin-containing supplements.
Inositol hexanicotinate (a niacin-related form) should be checked as it may relate to interaction risk.
Not mentioned in the label; form-specific interaction discussion not present in the provided sections.
Talk to a pharmacist or prescriber before combining atorvastatin with vitamin B supplements if you have prior statin intolerance or muscle issues.
Not explicitly stated in the label in this phrasing; the patient counseling language is more general and does not specify vitamin B supplements.
Talk to a pharmacist or prescriber before combining atorvastatin with vitamin B supplements if you have known liver disease or chronically elevated liver enzymes.
Not explicitly stated in the label in this phrasing.
Talk to a pharmacist or prescriber before combining atorvastatin with vitamin B supplements if you have kidney disease.
Not explicitly stated in the label in this phrasing.
Talk to a pharmacist or prescriber before combining atorvastatin with vitamin B supplements if you’re taking other medications that affect statin levels (for example, strong CYP3A4 inhibitors).
While the label discusses interactions with strong CYP3A4 inhibitors, the exact phrasing about consulting a pharmacist before combining vitamin B supplements is not explicit in the label.
Contradictions
Important Omissions
No explicit labeling guidance on Niacin-containing supplements beyond general interaction risk; form-specific interactions (e.g., inositol hexanicotinate) are not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label indicates potential myopathy with certain drug combinations and possible liver enzyme elevations; overall risk with vitamin B supplements appears low if not combining with recognized interacting agents, but niacin-containing products can modify risk and require monitoring.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Clarify in claims that the labeled interactions primarily involve lipid-modifying doses of niacin and other listed interacting agents; avoid extrapolating general B-vitamin interactions not explicitly described in the label. Include explicit reference to when monitoring is recommended (CPK, LFTs) in the context of B-vitamin-containing supplements if niacin is present.